These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
618 related articles for article (PubMed ID: 33764809)
41. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Holland EM; Molina JC; Dede K; Moyer D; Zhou T; Yuan CM; Wang HW; Stetler-Stevenson M; Mackall C; Fry TJ; Panch S; Highfill S; Stroncek D; Little L; Lee DW; Shalabi H; Yates B; Shah N J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35534047 [TBL] [Abstract][Full Text] [Related]
42. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217 [TBL] [Abstract][Full Text] [Related]
43. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386 [TBL] [Abstract][Full Text] [Related]
44. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532 [TBL] [Abstract][Full Text] [Related]
45. INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia. Winestone LE; Bhojwani D; Ghorashian S; Muffly L; Leahy AB; Chao K; Steineck A; Rössig C; Lamble A; Maude SL; Myers R; Rheingold SR Transplant Cell Ther; 2024 Jan; 30(1):56-70. PubMed ID: 37821078 [TBL] [Abstract][Full Text] [Related]
46. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914 [TBL] [Abstract][Full Text] [Related]
47. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075 [TBL] [Abstract][Full Text] [Related]
48. Are CAR T cells better than antibody or HCT therapy in B-ALL? Pulsipher MA Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):16-24. PubMed ID: 30504287 [TBL] [Abstract][Full Text] [Related]
49. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Wudhikarn K; Flynn JR; Rivière I; Gönen M; Wang X; Senechal B; Curran KJ; Roshal M; Maslak PG; Geyer MB; Halton EF; Diamonte C; Davila ML; Sadelain M; Brentjens RJ; Park JH Blood; 2021 Aug; 138(7):531-543. PubMed ID: 33851211 [TBL] [Abstract][Full Text] [Related]
51. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Holland EM; Yates B; Steinberg SM; Yuan CM; Wang HW; Annesley C; Shalabi H; Stroncek D; Fry TJ; Krueger J; Jacoby E; Hsieh E; Bhojwani D; Gardner RA; Maude SL; Shah NN Transplant Cell Ther; 2023 Sep; 29(9):574.e1-574.e10. PubMed ID: 37394115 [TBL] [Abstract][Full Text] [Related]
52. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944 [TBL] [Abstract][Full Text] [Related]
53. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Liang EC; Albittar A; Huang JJ; Hirayama AV; Kimble EL; Portuguese AJ; Chapuis A; Shadman M; Till BG; Cassaday RD; Milano F; Kiem HP; Riddell SR; Turtle CJ; Maloney DG; Gauthier J Blood Adv; 2023 Nov; 7(22):6990-7005. PubMed ID: 37774014 [TBL] [Abstract][Full Text] [Related]
54. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. Turtle CJ; Hanafi LA; Berger C; Gooley TA; Cherian S; Hudecek M; Sommermeyer D; Melville K; Pender B; Budiarto TM; Robinson E; Steevens NN; Chaney C; Soma L; Chen X; Yeung C; Wood B; Li D; Cao J; Heimfeld S; Jensen MC; Riddell SR; Maloney DG J Clin Invest; 2016 Jun; 126(6):2123-38. PubMed ID: 27111235 [TBL] [Abstract][Full Text] [Related]
55. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714 [TBL] [Abstract][Full Text] [Related]
56. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. Schultz LM; Eaton A; Baggott C; Rossoff J; Prabhu S; Keating AK; Krupski C; Pacenta H; Philips CL; Talano JA; Moskop A; Baumeister SHC; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Kunicki M; Mavroukakis S; Egeler E; Li Y; Mackall CL; Curran KJ; Verneris MR; Laetsch TW; Stefanski H J Clin Oncol; 2023 Jan; 41(2):354-363. PubMed ID: 36108252 [TBL] [Abstract][Full Text] [Related]
57. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia]. He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463 [No Abstract] [Full Text] [Related]
58. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Riddell SR; Maloney DG; Turtle CJ Blood; 2019 Aug; 134(7):636-640. PubMed ID: 31648294 [TBL] [Abstract][Full Text] [Related]
59. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630 [TBL] [Abstract][Full Text] [Related]
60. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]